Results 91 to 100 of about 1,024,322 (315)

Shenfu injection: a review of pharmacological effects on cardiovascular diseases

Frontiers in Pharmacology
Shenfu injection (SFI), composed of ginseng and aconite, is a Chinese patent developed from the classic traditional prescription Shenfu Decoction created more than 700 years ago.
Fei-Fei Xu, Fei-Fei Xu, Xiao-Fang Xie, Hai-Yan Hu, Rong-Sheng Tong, Cheng Peng   +5 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Pharmacology of marine toxins and cholinergic mechanisms [PDF]

, 1971
Thesis (M.Sc.) -- University of Adelaide, Dept.
Turner, Raymond Jeffry
core  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Alantolactone Inhibits Double Expression Lymphoma via Dual-Targeted Glycogen Synthase Kinase 3 Beta and B-Cell Lymphoma2

Blood and Lymphatic Cancer: Targets and Therapy
Jianhua Chen,1,* Qing Liao,1,2,* Sha Yang,1 Jiaojiao Bian,1 Xianfu Li,3 Lu Zhao,4 Dan Wen,1 Dazhang Bai,5 Chunlei Yu,1 Chunyang Zhou,1 Zhengmin Xu1,6 1Department of Pharmacology Institute of Materia Medica, School of Pharmacy, North ...
Chen J, Liao Q, Yang S, Bian J, Li X, Zhao L, Wen D, Bai D, Yu C, Zhou C, Xu Z   +10 more
doaj  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

The Pharmacology of Immunosuppression [PDF]

American Journal of Pharmaceutical Education, 2009
To provide students with a comprehensive, integrated presentation on the pharmacology of immuosuppression.Course content on the pharmacology of immunosuppression relating to organ transplantation and treatment of autoimmune disorders was presented in integrated sequence modules that included content from pharmacology, medicinal chemistry, and ...
openaire   +2 more sources

Pharmacology of antiepileptic drugs during pregnancy and lactation.

, 2007
Most women with epilepsy require continuous treatment during pregnancy, making antiepileptic drugs (AEDs) one of the most frequent chronic teratogen exposures.
PENNELL P. B., SABERS A., GORDON J., PERUCCA, EMILIO, FOR THE INTERNATIONAL AED PHARMACOLOGY WORK GROUP FOR THE HEALTH OUTCOMES IN PREGNANCY AND EPILEPSY FORUM, GIDAL B. E.   +5 more
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Editorial: New trends in natural product research for inflammatory and infectious diseases

Frontiers in Pharmacology, 2022
Jaime Ribeiro-Filho, Yanna Carolina Ferreira Teles, John Ogbaji Igoli, Raffaele Capasso   +3 more
doaj   +1 more source